A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03082209 |
|
Recruitment Status :
Recruiting
First Posted : March 17, 2017
Last Update Posted : October 5, 2018
|
Sponsor:
AbbVie
Information provided by (Responsible Party):
AbbVie
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RPTD), and evaluate the safety, efficacy, and pharmacokinetic (PK) profile of ABBV-621 for participants with previously treated solid tumors or hematologic malignancies.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Advanced Solid Tumors Cancer Hematologic Malignancies | Drug: ABBV-621 Drug: Venetoclax | Phase 1 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 155 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | An Open-Label, Phase 1, First-In-Human Study of Safety and Tolerability of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously Treated Solid Tumors and Hematologic Malignancies |
| Actual Study Start Date : | April 3, 2017 |
| Estimated Primary Completion Date : | February 2, 2021 |
| Estimated Study Completion Date : | February 24, 2021 |
Resource links provided by the National Library of Medicine
Drug Information available for:
Venetoclax
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Dose Escalation
ABBV-621 via intravenous administration at escalating dose levels in participants with solid tumors including Non-Hodgkin Lymphoma (NHL).
|
Drug: ABBV-621
Intravenous |
|
Experimental: Dose Optimization for KRAS-mutant CRC
Participants with colorectal cancer (CRC) will be treated with single-agent ABBV-621 to enable selection of the RP2D.
|
Drug: ABBV-621
Intravenous |
|
Experimental: Dose Optimization for Pancreatic Cancer
Participants with pancreatic cancer will be treated with single-agent ABBV-621 to enable selection of the recommended Phase 2 dose (RP2D).
|
Drug: ABBV-621
Intravenous |
|
Experimental: ABBV-621 + Venetoclax for DLBCL
Participants with diffuse large B-cell lymphoma (DLBCL) will be treated with a combination of ABBV-621 and venetoclax.
|
Drug: ABBV-621
Intravenous Drug: Venetoclax tablet, oral
Other Names:
|
|
Experimental: ABBV-621 Monotherapy for AML
Participants with Acute Myeloid Leukemia (AML) will be treated with ABBV-621 monotherapy.
|
Drug: ABBV-621
Intravenous |
|
Experimental: ABBV-621 + Venetoclax for AML
Additional participants with AML will be enrolled and will be treated with a combination of ABBV-621 and venetoclax.
|
Drug: ABBV-621
Intravenous Drug: Venetoclax tablet, oral
Other Names:
|
Primary Outcome Measures :
- Area under the serum concentration time curve (AUC) of ABBV-621 [ Time Frame: Up to 64 days ]Area under the serum concentration time curve (AUC) of ABBV-621.
- Maximum observed serum concentration (Cmax) of ABBV-621 [ Time Frame: Up to 64 days ]Maximum observed serum concentration (Cmax) of ABBV-621.
- Terminal phase elimination rate constant (β) [ Time Frame: Up to 64 days ]Terminal phase elimination rate constant (β).
- Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) for ABBV-621 [ Time Frame: Up to 21 days ]The MTD and/or RP2D of ABBV-621 will be determined during the dose escalation phase of the study of ABBV-621
- Time to Cmax (Tmax) of ABBV-621 [ Time Frame: Up to 64 days ]Time to Cmax (Tmax) of ABBV-621.
Secondary Outcome Measures :
- QTcF Change from Baseline [ Time Frame: Up to 64 days ]QT interval measurement corrected by Fridericia's formula (QTcF) mean change from baseline by dose level
- Number of Participants with Dose-limiting Toxicities (DLTs) [ Time Frame: Up to 42 days after first day of study drug administration or 14 days after bone marrow biopsy showing < 5% blast count (whichever is later) ]Dose limiting toxicities for dose escalation purposes will be determined on events that occur during the first 21-day cycle (with protocol specified exceptions for AML participants).
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 100 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Must have a diagnosis of a solid tumor (except primary brain tumors), acute myeloid leukemia (AML), or non-Hodgkin lymphoma (NHL); NHL may be of any subtype for Dose Escalation but is limited to diffuse large B-cell lymphoma (DLBCL) for those enrolled to the cohort evaluating the combination of ABBV-621 and venetoclax. Subjects in the Dose Optimization solid tumor cohorts must have either colorectal cancer with documented KRAS mutations (as determined by local testing), or pancreatic cancer (irrespective of mutational status).
- Must have received at least one prior systemic therapy, and must have relapsed or progressed after, or failed to respond to any/all available effective therapy or therapies.
- Must have measurable disease (by Response Evaluation Criteria In Solid Tumors [RECIST] 1.1 for those with solid tumors; by Lugano classification for those with NHL), except those with AML, who must have histologically confirmed relapsed or refractory disease.
- Must have an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 - 2.
- Must have adequate hematologic, renal and hepatic function.
Exclusion Criteria:
- Participants with history of brain metastases who have not shown clinical and radiographic stable disease for at least 28 days after definitive therapy.
- Presence of primary hepatobiliary malignancy, including cholangiocarcinoma or hepatocellular carcinoma, gallbladder carcinoma, cancer of ampulla of Vater.
- Receipt of any systemic anti-cancer agent, including investigational anti-cancer products, within 21 days prior to study drug administration or 3 half-lives, whichever is longer.
- Participant with a history of cirrhosis or other indication of significant possible hepatic dysfunction. Note: Those with non-alcoholic steatohepatitis (NASH) should be discussed with the AbbVie TA MD before enrollment.
- Participant with a positive diagnosis of hepatitis A, B, or C.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03082209
Contacts
| Contact: ABBVIE CALL CENTER | 847.283.8955 | abbvieclinicaltrials@abbvie.com |
Locations
| United States, Connecticut | |
| Yale University /ID# 158029 | Recruiting |
| New Haven, Connecticut, United States, 06510 | |
| United States, Illinois | |
| University of Chicago /ID# 158030 | Active, not recruiting |
| Chicago, Illinois, United States, 60637-1443 | |
| Ingalls Memorial Hosp /ID# 171221 | Recruiting |
| Harvey, Illinois, United States, 60426 | |
| United States, Rhode Island | |
| Rhode Island Hospital /ID# 171157 | Recruiting |
| Providence, Rhode Island, United States, 02903 | |
| United States, Texas | |
| MD Anderson Cancer Center /ID# 202187 | Not yet recruiting |
| Houston, Texas, United States, 77030 | |
| South Texas Accelerated Research Therapeutics /ID# 160574 | Recruiting |
| San Antonio, Texas, United States, 78229 | |
| United States, Wisconsin | |
| Medical College of Wisconsin /ID# 171152 | Not yet recruiting |
| Milwaukee, Wisconsin, United States, 53226-3522 | |
| Japan | |
| National Cancer Ctr Hosp East /ID# 160596 | Recruiting |
| Kashiwa-shi, Chiba, Japan, 277-8577 | |
| Yamagata University Hospital /ID# 200681 | Recruiting |
| Yamagata-shi, Yamagata, Japan, 990-9585 | |
| Netherlands | |
| Duplicate_Universitair Medisch Centrum Groningen /ID# 169748 | Recruiting |
| Groningen, Netherlands, 9700 RB | |
| Erasmus Medisch Centrum /ID# 160869 | Recruiting |
| Rotterdam, Netherlands, 3015 CE | |
| Universitair Medisch Centrum Utrecht /ID# 169747 | Recruiting |
| Utrecht, Netherlands, 3584 CX | |
| Spain | |
| Hospital General Vall D'Hebron /ID# 170809 | Not yet recruiting |
| Barcelona, Spain, 08035 | |
| Hospital Fundacion Jimenez Dia /ID# 200106 | Recruiting |
| Madrid, Spain, 28040 | |
| Hosp Univ Madrid Sanchinarro /ID# 165136 | Recruiting |
| Madrid, Spain, 28050 | |
Sponsors and Collaborators
AbbVie
Investigators
| Study Director: | AbbVie Inc. | AbbVie |
| Responsible Party: | AbbVie |
| ClinicalTrials.gov Identifier: | NCT03082209 History of Changes |
| Other Study ID Numbers: |
M15-913 2016-003887-37 ( EudraCT Number ) |
| First Posted: | March 17, 2017 Key Record Dates |
| Last Update Posted: | October 5, 2018 |
| Last Verified: | October 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | Yes | |
| Studies a U.S. FDA-regulated Device Product: | No | |
| Product Manufactured in and Exported from the U.S.: | No | |
Keywords provided by AbbVie:
|
Solid Tumors Hematologic Malignancies Cancer non-Hodgkin lymphoma |
acute myeloid leukemia (AML) colorectal cancer (CRC) Diffuse Large B-Cell Lymphoma (DLBCL) |
Additional relevant MeSH terms:
|
Neoplasms Venetoclax Antineoplastic Agents |